Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Association between Diabetic Control (HbA1C) and the Risk of Developing Neurological Post-Acute Sequelae of COVID-19 (PASC)
General Neurology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
Prior literature has reported that diabetes is a risk factor for PASC. 
To investigate HbA1c as an independent risk factor in neurological PASC.

COVID-19 inpatients from a tertiary care center were retrospectively studied for presence of neurological PASC symptoms, 4 weeks to up to 1 year after their first inpatient admission COVID-19. Patients who had an HbA1c measured were grouped: Group A, HbA1c below 5.7%; Group B, HbA1c between 5.7% and 6.4%; Group C, HbA1c between 6.5% and 9%; Group D, HbA1c above 9%. The incidence of neurological PASC symptoms was compared.

Of the 433 COVID-19 patients reviewed, 160 patients (37.0%) had an HbA1c level measured during hospital stay. Of these, 75 patients (46.9%) had an outpatient follow-up or were readmitted to the hospital. These 75 patients were divided by HbA1c level: Group A (30.7%), Group B (21.3%), Group C (30.7%), and Group D (20.0%) p>0.05. For Group A vs B vs C vs D, numbness (13.0% vs 6.25% vs 17.4% vs 13.3%) p>0.05, paresthesias (4.35% vs 0% vs 13.0% vs 20.0%) p>0.05, brain fog or cognitive impairment (8.70% vs 12.5% vs 8.70% vs 6.67%) p>0.05, weakness (30.4% vs 37.5% vs 13.0% vs 13.3%) p>0.05, fatigue (30.4% vs 31.3% vs 34.8% vs 26.7%) p>0.05, headaches (21.7% vs 25.0% vs 13.0% vs 20.0%) p>0.05, changes in smell of taste (13.0% or 18.8% vs 17.4% vs 13.3%) p>0.05, sleep issues or insomnia (4.35% vs 0% vs 13.0% vs 0%) p>0.05 and anxiety or depression (17.4% vs 18.8% vs 4.35% vs 26.7%) p>0.05.

This preliminary analysis demonstrates that there was no significant difference in the incidence of neurological PASC symptoms between the four groups. Work is in progress to look at HbA1c at multiple time points, expand the study size, increase the follow up time and adjust for comorbid and concomitant neurological conditions.

Anam Khalid Shaikh (New Jersey Medical School)
Miss Shaikh has nothing to disclose.
Muhammed Ors Mr. Ors has nothing to disclose.
Mustafa Jaffry Mr. Jaffry has nothing to disclose.
Kranthi Kiran Mandava Mr. Mandava has nothing to disclose.
Kazim Jaffry Mr. Jaffry has nothing to disclose.
Ronak Uday Trivedi Mr. Trivedi has nothing to disclose.
Iqra *Use 379943 Faiz, Masters student Ms. Faiz has nothing to disclose.
Firas Gerges (New Jersey Institute of Technology) Mr. Gerges has nothing to disclose.
Michel Boufadel (New Jersey Institute of Technology) Prof. Boufadel has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS) Dr. Souayah has received publishing royalties from a publication relating to health care.